fund

Mankind Pharma, Suzlon Energy among stocks that Motilal Oswal Midcap Fund bought & sold in December



Motilal Oswal Midcap Fund, the top performer in calendar year 2024, added Oracle Financial Services Software, Indraprastha Gas, and Mankind Pharma to its portfolio in December and made a complete exit from BSE, Bajaj Auto, Suzlon Energy, and Shaily Engineering Plastics in the same period.Motilal Oswal Midcap Fund is one of the best performing equity mutual funds in 2024 and offered the highest return of 57.51% in the calendar year 2024. We considered only pure equity categories for analysis such as large cap, mid cap, multi cap, flexi cap, ELSS, large & mid cap, small cap, focused fund, value and contra funds.

Also Read | Mutual funds increase cash allocation by Rs 7,000 crore to Rs 1.87 lakh crore in December

Around 1.30 crore shares of Indraprastha Gas were added to the portfolio, followed by 8 lakh shares of Mankind Pharma and 7.96 lakh shares of Oracle Financial Services Software in December.

The midcap fund sold 1.75 crore shares of Suzlon Energy from its portfolio in December. Around 11.25 lakh shares of Bajaj Auto were sold from the portfolio, followed by 2.99 lakh shares of BSE and 2.25 lakh shares of Shaily Engineering Plastics in the mentioned period.

The fund increased its exposure in 12 stocks which includes Trent, The Phoenix Mills, Supreme Industries, Coforge, KEI Industries, Bharti Hexacom, One97 Communications, Persistent Systems, Polycab India, Kalyan Jewellers, Jio Financial Services, and KPIT Technologies.

Around 30 lakh shares of Jio Financial Services were added to the portfolio on a monthly basis taking the total number of shares to 4.55 crore in December from 4.25 crore in November. It added 27.50 lakh shares of Kalyan Jewellers and 25 lakh shares of One97 Communications.

Read More   Dollar slips lower, continuing last week's selloff

The exposure in Bharti Hexacom was increased by adding 15.27 lakh shares to the portfolio and 12.50 lakh shares of Trent. It added 95,000 shares of Coforge.

The exposure in four stocks was reduced in the mentioned time period which includes Zomato, Deepak Nitrite, Mahindra & Mahindra, and Deepak Fertilisers And Petrochemicals Corporation. Around 6.39 crore shares of Zomato were sold from the portfolio taking the total number of stocks to 1.35 crore in December from 7.75 crore in November.

The midcap fund sold 17.10 lakh shares of Deepak Fertilisers And Petrochemicals Corporation in December, followed by 12.50 lakh shares of Mahindra & Mahindra and 11.02 of Deepak Nitrite.

Also Read | 3 stocks that India’s largest mutual fund scheme bought and sold in December

The exposure in seven stocks remained unchanged which included CG Power and Industrial Solutions, Voltas, Balkrishna Industries, Dixon Technologies (India), Prestige Estates Projects, Max Healthcare Institute, and Tube Investments of India.

Motilal Oswal Midcap Fund is an open ended equity scheme predominantly investing in mid cap stocks. The objective of the scheme is to achieve long term capital appreciation by investing in quality mid-cap companies having long-term competitive advantages and potential for growth.

The scheme is benchmarked against Nifty Midcap 150 Total Return Index and is managed by Niket Shah, Rakesh Shetty, and Ankush Sood. The mid cap fund allocates 65-100% in equity and equity related instruments selected between Top 101st and 250th listed companies by full market capitalization, 0-35% in equity and equity related instruments of companies other than the ones selected between Top 101st and 250th listed companies by full market capitalization, 0-35% in debt, money market instruments, g-sec, bonds, cash and cash equivalents, etc, and 0-10% in units issued by REITs and InvITs.

Read More   LSEG says FX system briefly impacted by technical glitch, it is investigating

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.